Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.57 +0.66 (+3.69%)
Streaming Delayed Price Updated: 3:46 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Looking Into Legend Biotech's Recent Short Interest ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Legend Biotech Through 6 Analysts ↗
 
Via Benzinga
News headline image
The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
News headline image
Is Legend Biotech Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
What Does the Market Think About Legend Biotech? ↗
 
Via Benzinga
News headline image
Is Legend Biotech Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Peering Into Legend Biotech's Recent Short Interest ↗
 
Via Benzinga
News headline image
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Where Legend Biotech Stands With Analysts ↗
 
Via Benzinga
News headline image
Breaking Down Legend Biotech: 9 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
(LEGN) - Analyzing Legend Biotech's Short Interest ↗
 
Via Benzinga
News headline image
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst ↗
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
News headline image
5 Analysts Have This To Say About Legend Biotech ↗
 
Via Benzinga
News headline image
What Does the Market Think About Legend Biotech? ↗
 
Via Benzinga
News headline image
Demystifying Legend Biotech: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.